Neuromodulation Devices — The OTC Options Your Patients May Already Be Using

Four FDA-cleared neuromodulation devices are available for migraine — two without a prescription. Document patient device use before filing a PA: it satisfies non-pharmacological step therapy requirements and strengthens the clinical narrative.

PA impact: This card directly affects prior authorization outcomes. Documentation language from this card can be used in PA letters and appeals.

Four FDA-cleared neuromodulation devices are now available for migraine treatment. Two of them — Cefaly and Truvaga — require no prescription and are available directly to consumers. Many patients are using these tools without mentioning them during visits. This card covers the full device landscape, how to route insurance claims correctly for the prescription versions, and why asking about device use before writing a PA strengthens your documentation.

The Device Landscape

All four devices work through non-pharmacological mechanisms — none carry MOH risk, none interact with migraine medications, and all are appropriate as adjunct therapy alongside preventive and acute treatments.

| Device | Mechanism | Rx? | Cost Model | Insurance | HCPCS | |---|---|---|---|---|---| | Truvaga (consumer Gammacore) | Noninvasive VNS, neck, 2 min/session | No | One-time: ~$199 (350 sessions, disposable) or ~$350+ (Plus, unlimited/rechargeable) | Not covered. HSA/FSA eligible. | — | | Cefaly | eTNS (trigeminal nerve, forehead), acute + preventive modes | No | ~$379–$499 device (one-time) + ~$25/mo electrodes | No contracts yet (actively pursuing). VA covered. HSA/FSA eligible. Submit E0733 for possible reimbursement. | E0733 | | Nerivio | Remote electrical neuromodulation (arm-worn), acute + preventive | Yes | Per-refill ~$89 (savings program). $45 online Rx consult available. | Growing coverage: Anthem BCBS (~80M members), VA, multiple state Medicaid programs. | A4540 | | Gammacore (Rx version) | Noninvasive VNS, neck | Yes | Prescription. Copay assistance available via electroCore. | Variable commercial. UHC 2025 policy: tVNS "not medically necessary" — see UHC note below. | — |

Ask Your Patient Before Filing a PA

Patients using OTC devices often don't volunteer this information — they don't think it's medically relevant. Asking directly serves two purposes: it completes your clinical picture, and it adds a treatment modality to your PA documentation. A patient who reports partial benefit from a neuromodulation device but still requires pharmacological prevention is a stronger PA candidate than one with no documented adjunct treatment attempts.

Documentation template: "Patient has been using [device] for [duration] with [reported outcome]. Non-pharmacological adjunct treatment has been pursued. Pharmacological preventive therapy remains indicated based on [frequency] migraine days per month and [score] functional impact."

This language satisfies behavioral/non-pharmacological step therapy requirements at payers that list them (e.g., Kaiser) and pre-empts reviewer questions about lifestyle intervention.

OTC Device Details

Truvaga (consumer Gammacore — electroCore). Noninvasive vagus nerve stimulation via neck placement, 2-minute sessions. No prescription required. Available at retail and directly from truvaga.com. Two models: Truvaga 350 (~$199, preloaded with 350 sessions then disposed of) and Truvaga Plus (~$350+, unlimited sessions, rechargeable, app-required). Technically near-identical to Gammacore Rx, which carries FDA clearance for episodic cluster headache. Truvaga is positioned as a consumer wellness product — this keeps it OTC but means it does not carry Gammacore's FDA migraine/cluster indication. HSA/FSA eligible. Not covered by commercial insurance as Truvaga.

Cefaly. External trigeminal neurostimulation (eTNS) via forehead electrode. No prescription required. Two FDA-cleared modes: PREVENT (20 minutes daily as a preventive) and ACUTE (60 minutes during an attack for acute relief) — separate evidence bases and separate FDA clearances. Device ~$379–$499 one-time; electrodes ~$25/month ongoing. HCPCS code E0733 exists for insurance reimbursement attempts — instruct patients to ask their insurer about DME coverage under E0733 rather than asking by brand name. As of 2026, Cefaly does not have contracts with commercial payors, Medicaid, or Medicare, but is actively pursuing payor contracting. VA healthcare covers Cefaly. HSA/FSA eligible.

Prescription Device Details

Nerivio (Theranica). Remote electrical neuromodulation (REN) via arm-worn device, controlled by smartphone app. FDA-cleared for both acute treatment and prevention (every-other-day for preventive). Cleared for patients 8 years and older — one of the few non-drug migraine options for pediatric patients. Requires prescription. Per-refill cost model; savings program caps out-of-pocket at $89/refill for insured patients without coverage. A $45 online telemedicine consultation is available for patients whose providers are unfamiliar with the device. HCPCS code A4540. Insurance coverage is expanding: Anthem BCBS (covering approximately 80 million members across 20 states), VA, and several state Medicaid programs now cover Nerivio.

Gammacore (electroCore, Rx version). Prescription VNS device — same mechanism as Truvaga, higher maximum output. FDA-cleared for acute treatment of pain associated with episodic cluster headache. Coverage is variable across commercial plans. Copay assistance available through electroCore's patient support program.

⚠️ UHC Coverage Note — Flag Before Patient Attempts Prior Auth

UnitedHealthcare's 2025 medical policy classifies transcutaneous (non-implantable) VNS devices and external trigeminal nerve stimulation devices as "unproven and not medically necessary" for all indications. This affects Gammacore Rx and Cefaly insurance reimbursement attempts under UHC specifically. Practical implication: Patients with UHC who purchase Cefaly OTC and attempt reimbursement via E0733 are likely to be denied under this policy. Patients seeking Gammacore Rx under UHC face the same barrier. Set expectations before patients invest time in the appeals process. The OTC consumer path (Truvaga, Cefaly purchased directly) remains available regardless of insurer.

Supplements — Cross-Reference to Smart Phrase Library

Magnesium (glycinate or oxide), Riboflavin (B2), and CoQ10 have Level B/C evidence from the American Headache Society for migraine prevention. Full documentation guidance is in the Smart Phrase Library .vaultbehavioral phrase — use that for charting. The table below is a quick clinical reference.

| Supplement | AHS Evidence | Clinical notes | |---|---|---| | Magnesium glycinate or oxide | Level B | 400–600mg daily. GI side effects (loose stool) at higher doses — glycinate form generally better tolerated. Safe to recommend without specialist input. | | Riboflavin (Vitamin B2) | Level B | 400mg daily. Urine turns bright yellow — harmless, but warn patients. Takes 3 months to evaluate adequately. Low cost, widely available. | | Coenzyme Q10 (CoQ10) | Level C | 100–300mg daily. Less evidence than magnesium or B2 but well-tolerated. Reasonable to include in a supplement regimen alongside Level B options. |

Key PA point: None of these supplements cause medication overuse headache. None count as oral preventive steps for step therapy purposes. Their use is additive to, not a substitute for, pharmacological prevention. If a payer lists "behavioral or non-pharmacological treatment" as a step therapy requirement, documented supplement use alongside the .vaultbehavioral phrase satisfies that requirement at most payers.

Ready to run a PA?

The PA Engine applies this guidance automatically — paste a clinical note and get a complete, payer-specific PA letter in under a minute. Free, no account required.

Citations: Ailani J et al., AHS Consensus Statement, Headache 2021;61(7):1021-1039 (supplement evidence levels) | Schoenen J et al., Neurology 1998;50(2):466-470 (B2 RCT) | Sandor PS et al., Neurology 2005;64(4):713-715 (CoQ10 RCT) | Peikert A et al., Cephalalgia 1996;16(4):257-263 (magnesium RCT) | electroCore prescribing information (Gammacore) | Theranica FDA clearance documentation (Nerivio) | Cefaly Technology FDA clearance documentation | UnitedHealthcare Medical Policy: Vagus and External Trigeminal Nerve Stimulation, 2025.

Related cards